SKB500

DRUG2 trials

Sponsors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Conditions

Advanced Solid TumorsEsophageal Squamous Cell Carcinoma

Phase 1

A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors

RecruitingNCT06736327

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Advanced Solid Tumors

Start: 2024-12-13End: 2028-12-31Target: 180Updated: 2026-05-08

Phase 2

SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

RecruitingNCT07700667

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Esophageal Squamous Cell Carcinoma

Start: 2026-08-13End: 2029-12-31Target: 120Updated: 2026-08-26

Related Papers

An open-label, first-in-human study of SKB500 in patients with locally advanced or metastatic solid tumors.

Journal of Clinical Oncology2026-05-27